Hypertrophy of the heart - A new therapeutic target?

被引:700
作者
Frey, N
Katus, HA
Olson, EN
Hill, JA
机构
[1] Univ Texas, SW Med Ctr, Dept Internal Med, Div Cardiol, Dallas, TX 75390 USA
[2] Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA
[3] Univ Texas, SW Med Ctr, Donald W Reynolds Cardiovasc Clin Res Ctr, Dallas, TX 75390 USA
[4] Heidelberg Univ, Dept Cardiol Innere Med 3, Heidelberg, Germany
关键词
hypertrophy; heart failure; signal transduction;
D O I
10.1161/01.CIR.0000120390.68287.BB
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent studies call into question the necessity of hypertrophic growth of the heart as a "compensatory" response to hemodynamic stress. These findings, coupled with recent progress in dissecting the molecular bases of hypertrophy, raise the prospect of suppressing hypertrophy without provoking circulatory insufficiency. In this article, we focus on signaling pathways that hold promise as potential targets for therapeutic intervention. We also summarize observations from animal models and clinical trials that suggest benefit from an antihypertrophic strategy.
引用
收藏
页码:1580 / 1589
页数:10
相关论文
共 141 条
  • [1] A Ras-dependent pathway regulates RNA polymerase II phosphorylation in cardiac myocytes: Implications for cardiac hypertrophy
    Abdellatif, M
    Packer, SE
    Michael, LH
    Zhang, D
    Charng, MJ
    Schneider, MD
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (11) : 6729 - 6736
  • [2] Enhanced Gαq signaling:: A common pathway mediates cardiac hypertrophy and apoptotic heart failure
    Adams, JW
    Sakata, Y
    Davis, MG
    Sah, VP
    Wang, YB
    Liggett, SB
    Chien, KR
    Brown, JH
    Dorn, GW
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (17) : 10140 - 10145
  • [3] Roles of cardiac transcription factors in cardiac hypertrophy
    Akazawa, H
    Komuro, I
    [J]. CIRCULATION RESEARCH, 2003, 92 (10) : 1079 - 1088
  • [4] Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy
    Akhter, SA
    Luttrell, LM
    Rockman, HA
    Iaccarino, G
    Lefkowitz, RJ
    Koch, WJ
    [J]. SCIENCE, 1998, 280 (5363) : 574 - 577
  • [5] Diuretic versus α-blocker as first-step antihypertensive therapy -: Final results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    Alderman, MH
    [J]. HYPERTENSION, 2003, 42 (03) : 239 - 246
  • [6] *ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
  • [7] Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo
    Antos, CL
    McKinsey, TA
    Frey, N
    Kutschke, W
    McAnally, J
    Shelton, JM
    Richardson, JA
    Hill, JA
    Olson, EN
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (02) : 907 - 912
  • [8] Electrical and structural remodeling of the failing ventricle
    Armoundas, AA
    Wu, R
    Juang, G
    Marbán, E
    Tomaselli, GF
    [J]. PHARMACOLOGY & THERAPEUTICS, 2001, 92 (2-3) : 213 - 230
  • [9] Peroxisome proliferator-activated receptor γ plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo
    Asakawa, M
    Takano, H
    Nagai, T
    Uozumi, H
    Hasegawa, H
    Kubota, N
    Saito, T
    Masuda, Y
    Kadowaki, T
    Komuro, I
    [J]. CIRCULATION, 2002, 105 (10) : 1240 - 1246
  • [10] Fas receptor signaling inhibits glycogen synthase kinase 3β and induces cardiac hypertrophy following pressure overload
    Badorff, C
    Ruetten, H
    Mueller, S
    Stahmer, M
    Gehring, D
    Jung, F
    Ihling, C
    Zeiher, AM
    Dimmeler, S
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (03) : 373 - 381